Medicine guide
HumaSPECT
·
- Prescription status not stated
- Everything that fits nowhere else, such as contrast media
- Active substance
- Votumumab
- Made by
- KS Biomedix Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- After reconstitution with sodium pertechnetate [99mTc] solution, HumaSPECT [99mTc] is indicated in patients with histologically proven carcinoma of the colon or rectum for imaging of recurrence and/or metastases. HumaSPECT [99mTc] is employed, in the above mentioned patients, as an adjunct to standard non invasive imaging techniques, such as ultrasonography or CT scan, in the following situations.• Patients with evidence of recurrence and/or metastatic carcinoma of the colon or rectum, who are undergoing an evaluation for extent of disease, such as prior to surgical resection and/or other therapy.• Patients with suspected recurrence and/or metastatic carcinoma of the colon or rectum in association with rising levels of carcinoembryonic antigen (CEA).
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | KS Biomedix Limited |
|---|---|
| Active substance | Votumumab |
| Used in | Everything that fits nowhere else, such as contrast media |
| Classification | V09IX · Everything that fits nowhere else, such as contrast media |
| Authorised on | 1998-09-25 |
| Last updated by the regulator | 2004-02-23 |
| EMA product number | EMEA/H/C/000145 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).